You just read:

Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology

News provided by

Eisai Inc.

Mar 19, 2020, 14:45 ET